Abound Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Abound Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7	Closed	-$156	–	1366
2026 Q1	$156	Hold	7	–	–	﹤0.01%	1309
2025 Q4	$187	Hold	7	–	–	﹤0.01%	1206
2025 Q3	$150	Hold	7	–	–	﹤0.01%	1221
2025 Q2	$151	Hold	7	–	–	﹤0.01%	1136
2025 Q1	$117	Buy	+7	New	+$127	﹤0.01%	1193

Other funds holding ACAD

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Abound Wealth Management's ACAD Position: Q2 2026 in Review

Abound Wealth Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 7 shares — an estimated $156 sold.

Abound Wealth Management first reported a position in ACAD in Q1 2025 and held it in 5 quarters. The position peaked at $187 in Q4 2025. 36 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Abound Wealth Management reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Abound Wealth Management sold 7 Acadia Pharmaceuticals shares in Q2 2026, an estimated $156.
Abound Wealth Management first reported a position in Acadia Pharmaceuticals in Q1 2025 and held it in 5 quarters.
Abound Wealth Management's Acadia Pharmaceuticals position peaked at $187 in Q4 2025.
36 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.